Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Gram-negative Bacterial Infection Clinical Trial

Official title: First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An3365 In Single And Multiple Doses In Young Healthy Subjects

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.

Clinical Trial Description

Single-center, randomized, placebo-controlled, double-blind study to determine the safety, tolerability and pharmacokinetic profile of compound in single and multiple doses in young healthy males. ;

Related Conditions & MeSH terms

• Bacterial Infections
• Communicable Diseases
• Gram-negative Bacterial Infection
• Gram-Negative Bacterial Infections
• Infection

• NCT number: NCT01015014
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 1
• Start date: November 5, 2009
• Completion date: May 13, 2010